Literature DB >> 29391602

Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Jinah Park1, Junil Kim2,3, Bora Park1, Kyung-Min Yang1, Eun Jin Sun1, Cristina E Tognon4, Poul H Sorensen5, Seong-Jin Kim6,7.   

Abstract

Chromosomal rearrangements that facilitate tumor formation and progression through activation of oncogenic tyrosine kinases are frequently observed in cancer. The ETV6-NTRK3 (EN) fusion has been implicated in various cancers, including infantile fibrosarcoma, secretory breast carcinoma, and acute myeloblastic leukemia, and has exhibited in vivo and in vitro transforming ability. In the present study, we analyzed transcriptome alterations using DNA microarray and RNA-Seq in EN-transduced NIH3T3 fibroblasts to identify the mechanisms that are involved in EN-mediated tumorigenesis. Through functional profile assessment of EN-regulated transcriptome alterations, we found that upregulated genes by EN were mainly associated with cell motion, membrane invagination, and cell proliferation, while downregulated genes were involved in cell adhesion, which correlated with the transforming potential and increased proliferation in EN-transduced cells. KEGG pathway analysis identified the JAK-STAT signaling pathway with the highest statistical significance. Moreover, Ingenuity Pathway Analysis and gene regulatory network analysis identified the STAT1 transcription factor and its target genes as top EN-regulated molecules. We further demonstrated that EN enhanced STAT1 phosphorylation but attenuated STAT1 acetylation, eventually inhibiting the interaction between the NF-κB p65 subunit and acetylated STAT1. Consequently, nuclear translocation of NF-κB p65 and subsequent NF-κB activity were increased by EN. Notably, inhibition of STAT1 phosphorylation attenuated tumorigenic ability of EN in vitro and in vivo. Taken together, here we report, for the first time, STAT1 as a significant EN-regulated transcription factor and a crucial mediator of EN-induced tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29391602     DOI: 10.1038/s41388-017-0102-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.

Authors:  D H Wai; S R Knezevich; T Lucas; B Jansen; R J Kay; P H Sorensen
Journal:  Oncogene       Date:  2000-02-17       Impact factor: 9.867

2.  Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands.

Authors:  Justin A Bishop; Janis M Taube; Albert Su; Scott W Binder; Dmitry V Kazakov; Michal Michal; William H Westra
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

3.  H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs.

Authors:  Jiekai Chen; He Liu; Jing Liu; Jing Qi; Bei Wei; Jiaqi Yang; Hanquan Liang; You Chen; Jing Chen; Yaran Wu; Lin Guo; Jieying Zhu; Xiangjie Zhao; Tianran Peng; Yixin Zhang; Shen Chen; Xuejia Li; Dongwei Li; Tao Wang; Duanqing Pei
Journal:  Nat Genet       Date:  2012-12-02       Impact factor: 38.330

Review 4.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

Review 5.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

6.  STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations.

Authors:  Maria Adamaki; Maria Tsotra; Spiros Vlahopoulos; Archontis Zampogiannis; Athanasios G Papavassiliou; Maria Moschovi
Journal:  Leuk Res       Date:  2015-09-11       Impact factor: 3.156

Review 7.  RNA-Seq: a revolutionary tool for transcriptomics.

Authors:  Zhong Wang; Mark Gerstein; Michael Snyder
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

Review 8.  ALK inhibitors in the treatment of advanced NSCLC.

Authors:  Cesare Gridelli; Solange Peters; Assunta Sgambato; Francesca Casaluce; Alex A Adjei; Fortunato Ciardiello
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

9.  Architecture of the human regulatory network derived from ENCODE data.

Authors:  Mark B Gerstein; Anshul Kundaje; Manoj Hariharan; Stephen G Landt; Koon-Kiu Yan; Chao Cheng; Xinmeng Jasmine Mu; Ekta Khurana; Joel Rozowsky; Roger Alexander; Renqiang Min; Pedro Alves; Alexej Abyzov; Nick Addleman; Nitin Bhardwaj; Alan P Boyle; Philip Cayting; Alexandra Charos; David Z Chen; Yong Cheng; Declan Clarke; Catharine Eastman; Ghia Euskirchen; Seth Frietze; Yao Fu; Jason Gertz; Fabian Grubert; Arif Harmanci; Preti Jain; Maya Kasowski; Phil Lacroute; Jing Jane Leng; Jin Lian; Hannah Monahan; Henriette O'Geen; Zhengqing Ouyang; E Christopher Partridge; Dorrelyn Patacsil; Florencia Pauli; Debasish Raha; Lucia Ramirez; Timothy E Reddy; Brian Reed; Minyi Shi; Teri Slifer; Jing Wang; Linfeng Wu; Xinqiong Yang; Kevin Y Yip; Gili Zilberman-Schapira; Serafim Batzoglou; Arend Sidow; Peggy J Farnham; Richard M Myers; Sherman M Weissman; Michael Snyder
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

10.  SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks.

Authors:  Dávid Fazekas; Mihály Koltai; Dénes Türei; Dezső Módos; Máté Pálfy; Zoltán Dúl; Lilian Zsákai; Máté Szalay-Bekő; Katalin Lenti; Illés J Farkas; Tibor Vellai; Péter Csermely; Tamás Korcsmáros
Journal:  BMC Syst Biol       Date:  2013-01-18
View more
  2 in total

Review 1.  JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression.

Authors:  Katie L Owen; Natasha K Brockwell; Belinda S Parker
Journal:  Cancers (Basel)       Date:  2019-12-12       Impact factor: 6.639

2.  HCV and flaviviruses hijack cellular mechanisms for nuclear STAT2 degradation: Up-regulation of PDLIM2 suppresses the innate immune response.

Authors:  Michael A Joyce; Karyn M Berry-Wynne; Theodore Dos Santos; William R Addison; Nicola McFarlane; Tom Hobman; D Lorne Tyrrell
Journal:  PLoS Pathog       Date:  2019-08-02       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.